Navigation Links
Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
Date:5/18/2009

SAN FRANCISCO, May 18 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.

"A significant number of pediatric ADHD patients present with behaviors such as anger, resentfulness, defiance, and arguing with adults. It can be complicated for physicians and caregivers to find the right medication to control symptoms for children with ADHD exhibiting these behaviors," said Daniel Connor, MD, professor and division chief of child and adolescent psychiatry at the University of Connecticut Medical School. "When considered with the primary efficacy results of the current study, these data provide additional support for the clinical efficacy of INTUNIV for treating ADHD in this patient population."

On January 26, 2009, Shire filed a resubmission to the US Food and Drug Administration (FDA) of the New Drug Application to support approval for the treatment of ADHD in children and adolescents. Once available, INTUNIV will be the first selective alpha-2A receptor agonist approved for the treatment of ADHD.

INTUNIV Demonstrated Significant Efficacy in Secondary Endpoints

In this randomized, placebo-controlled, flexible-dose study, INTUNIV demonstrated significant ADHD symptom improvement in patients with oppositional symptoms as measured by the
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
2. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
3. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
6. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
7. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... April 18, 2012  CAQH® announced today that ... the Universal Provider Datasource® (UPD®), demonstrating that ... standard for self-reported provider data used to ... network directories, referrals and claims administration. ...
... Live has revealed further details of the newest event ... (SEA) 2012. Set to debut from 10-12 May 2012 at ... first trade show and exhibition of its kind to be ... CPhI SEA will provide a meeting place ...
Cached Medicine Technology:One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 2One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:4/24/2014)... A national response to the epidemic of prescription opioid ... England Journal of Medicine by leaders of agencies ... The commentary calls upon health care providers to ... and reduce overdose deaths, and describes a number of ... medications. The commentary also discusses how medications can be ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... for a new experimental drug to treat acute ... with CPX-351, a combination of the chemotherapeutic drugs ... patients treated with the standard drug formulation. ... aggressive blood cancer with very low rates of ... Lancet, M.D., senior member of the Department of ...
(Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... done too soon can lead to respiratory trouble, other ... -- The rise in Caesarean deliveries could be fueling ... these early births carry risks, including respiratory problems, jaundice ... Tuesday during a March of Dimes conference in New ...
... been selected as the Grand Prize winner of the Jump Start ... ... Hudson, OH (PRWEB) December 18, 2008 -- A resident of ... the Jump Start ,09 national online sweepstakes sponsored by ActiveAmericans.com ...
... wellness center, will implement the C4 IP™ hosted VoIP and ... ... Atlanta, GA (PRWEB) December 18, 2008 -- ... implement the C4 IP™ hosted VoIP and ...
... recognize human gestures could provide a new way for ... related system for the able bodied could also be ... is described in detail in a forthcoming issue of ... , Manolya Kavakli of the Virtual and Interactive Simulations ...
... up after 3 years, study finds , , THURSDAY, Dec. 18 ... medication to prevent narrowing of the artery do better one ... stents, a new study shows. , However, within three years ... a greater risk of more surgery to increase blood flow ...
... Group-based treatment programs may effectively combat childhood obesity ... Florida study. , Children who participated in one of ... less overweight compared with children in a control group. ... Archives of Pediatric and Adolescent Medicine . , The ...
Cached Medicine News:Health News:Elective Early Deliveries Pose Risks for Babies 2Health News:Elective Early Deliveries Pose Risks for Babies 3Health News:Pittsburgh Area Resident Wins $15,000 In Online Sweepstakes 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 3Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 4Health News:Gesture recognition 2Health News:Coated Stents Better Than Bare Metal Ones in Short Run 2Health News:Group treatment may help children achieve healthier weights 2Health News:Group treatment may help children achieve healthier weights 3
... in Canons DR innovations, the CXDI-31 is ... a compact and lightweight design, the Canon ... conventional screen-film cassettes. It is designed to ... to get with fixed devices and supports ...
... a cost-effective synthetic bone filler tailored ... Phosphate (TCP) and Hydroxyapatite (HAP), its ... BAB formulates the chemistry and microstructure ... This formulation provides optimal osteo-conduction. The ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... TAU Lead is a ... stimulation lead for temporary ... The unique shaft design ... straight or preformed stylets ...
Medicine Products: